Microtubules as a target for anticancer drugs

Mary Ann Jordan,Leslie Wilson
DOI: https://doi.org/10.1038/nrc1317
IF: 78.5
2004-04-01
Nature Reviews Cancer
Abstract:Key PointsMicrotubules are highly dynamic cytoskeletal fibres that are composed of tubulin subunits. They show two types of non-equilibrium dynamics — treadmilling and dynamic instability — both of which are crucial to mitosis and cell division.Dynamic microtubules continue to be one of the most successful cancer chemotherapeutic targets. Many new drugs that target microtubules are in clinical trials and large numbers of microtubule-active compounds are being developed.Among the most successful microtubule-targeted chemotherapeutic drugs are paclitaxel and the Vinca alkaloids, which were previously thought to work through opposite mechanisms. We now recognize that their most potent actions are suppression of microtubule dynamics, rather than increasing or decreasing microtubule-polymer mass.Microtubule-active drugs generally bind to one of three main classes of sites on tubulin, the paclitaxel site, the Vinca domain and the colchicine domain. Drugs that bind to the colchicine domain are undergoing intensive investigation as vascular-targeting agents for cancer therapy.Development of resistance to microtubule-targeted drugs has several possible causes, some of which might involve changes in microtubule dynamics resulting from altered expression of tubulin isotypes, tubulin mutations, and altered expression or binding of microtubule-regulatory proteins.Microtubule-targeted drugs can synergize with one another.Understanding their modes of action might lead to improved dosing regimens and combinations with other microtubule-targeted drugs, as well as combinations with 'molecularly targeted' drugs.
oncology
What problem does this paper attempt to address?